Profile data is unavailable for this security.
About the company
Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.
- Revenue in AUD (TTM)0.00
- Net income in AUD-11.31m
- Incorporated2020
- Employees--
- LocationChimeric Therapeutics LtdLevel 3, 62 Lygon Street, CarltonMELBOURNE 3053AustraliaAUS
- Phone+61 39824-5254
- Fax+61 39822-7735
- Websitehttps://chimerictherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiopharm Theranostics Ltd | 0.00 | -46.82m | 18.07m | -- | -- | 0.6134 | -- | -- | -0.1343 | -0.1343 | 0.00 | 0.0652 | 0.00 | -- | -- | -- | -63.11 | -- | -77.85 | -- | -- | -- | -- | -- | -- | -7.48 | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Argent BioPharma Ltd | 1.32m | -17.02m | 18.34m | -- | -- | 10.90 | -- | 13.85 | -3.32 | -3.32 | 0.1003 | 0.0372 | 0.0813 | 0.7078 | 1.58 | -- | -105.32 | -111.29 | -345.98 | -171.05 | 21.87 | 32.52 | -1,295.20 | -632.42 | 0.6561 | -24.85 | 0.4104 | -- | -28.41 | 47.31 | -2.34 | -- | -16.20 | -- |
| Noxopharm Ltd | 3.90m | -12.13m | 18.41m | 1.00k | -- | 2.80 | -- | 4.72 | -0.0415 | -0.0415 | 0.0134 | 0.0225 | 0.2684 | -- | 1.64 | 3,901.84 | -83.43 | -50.96 | -94.78 | -62.98 | -- | -- | -310.82 | -191.70 | -- | -1.47 | 0.00 | -- | 11.32 | 44.02 | 19.34 | -- | -- | -- |
| Algorae Pharmaceuticals Ltd | 84.10k | -2.25m | 18.56m | -- | -- | 5.12 | -- | 220.70 | -0.0015 | -0.0015 | 0.00006 | 0.0022 | 0.0245 | -- | 1.79 | -- | -65.51 | -46.12 | -70.91 | -53.52 | -- | -- | -2,678.04 | -591.05 | -- | -136.75 | 0.00 | -- | 1,132.26 | -44.06 | -7.68 | -- | -- | -- |
| Acrux Ltd | 14.46m | -709.00k | 18.61m | 43.00 | -- | 3.29 | -- | 1.29 | -0.0024 | -0.0024 | 0.0502 | 0.0195 | 1.29 | -- | 4.86 | -- | -6.34 | -39.91 | -9.21 | -46.00 | 72.38 | -- | -4.90 | -132.53 | -- | -- | 0.2861 | -- | 133.74 | 28.29 | 92.23 | -- | -16.66 | -- |
| Rhythm Biosciences Ltd | 157.67k | -8.63m | 19.64m | -- | -- | 14.36 | -- | 124.56 | -0.0386 | -0.0386 | 0.0007 | 0.0055 | 0.0263 | -- | 1.81 | -- | -144.00 | -106.11 | -169.71 | -125.51 | -1,899.74 | -1,210.71 | -5,473.20 | -6,642.26 | 2.04 | -- | 0.0304 | -- | 814.18 | 28.77 | 6.55 | -- | -20.43 | -- |
| LTR Pharma Ltd | -100.00bn | -100.00bn | 19.71m | -- | -- | 6.21 | -- | -- | -- | -- | -- | 0.0451 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -41.65 | -- | -- | -- |
| Immuron Ltd | 3.58m | -3.88m | 20.29m | 6.00 | -- | 1.16 | -- | 5.67 | -0.017 | -0.017 | 0.0157 | 0.0769 | 0.1664 | 0.6468 | 7.92 | 596,106.70 | -18.06 | -27.48 | -19.86 | -29.58 | 80.87 | 77.52 | -108.52 | -296.64 | 7.79 | -2.85 | 0.0023 | -- | 135.85 | -13.34 | -32.66 | -- | 3.27 | -- |
| Syntara Ltd | 9.83m | -14.26m | 21.49m | 107.00 | -- | 2.39 | -- | 2.19 | -0.0197 | -0.0172 | 0.0136 | 0.0075 | 0.442 | 1.58 | 2.22 | -- | -64.13 | -27.33 | -97.76 | -34.23 | 81.69 | 88.37 | -145.11 | -61.99 | 1.75 | -262.59 | 0.0674 | -- | 23.60 | -18.30 | -486.78 | -- | -31.06 | -- |
| Chimeric Therapeutics Ltd | 0.00 | -11.31m | 23.12m | -- | -- | 1.41 | -- | -- | -0.027 | -0.027 | 0.00 | 0.0191 | 0.00 | -- | -- | -- | -45.96 | -- | -69.36 | -- | -- | -- | -- | -- | -- | -10.01 | 0.1596 | -- | -- | -- | -60.40 | -- | -- | -- |
| BCAL Diagnostics Ltd | 3.67m | -5.00m | 23.72m | -- | -- | 3.90 | -- | 6.45 | -0.0227 | -0.0227 | 0.0166 | 0.0241 | 0.4493 | -- | 3.21 | -- | -61.10 | -54.01 | -67.83 | -62.57 | -- | -- | -136.00 | -248.64 | -- | -131.83 | 0.1985 | -- | 298.63 | 63.18 | -49.51 | -- | 91.62 | -- |
| Lumos Diagnostics Holdings Ltd | 12.41m | -13.33m | 24.07m | -- | -- | 1.73 | -- | 1.94 | -0.0358 | -0.0358 | 0.0352 | 0.029 | 0.3418 | 2.24 | 6.37 | -- | -36.70 | -40.15 | -55.14 | -56.67 | 59.73 | 45.97 | -107.38 | -162.90 | 0.479 | -6.25 | 0.4803 | -- | -9.42 | 39.29 | 80.38 | -- | -38.50 | -- |
| LBT Innovations Limited | 2.00m | -21.38m | 24.11m | 17.00 | -- | 8.88 | -- | 12.03 | -0.0428 | -0.0428 | 0.0038 | 0.002 | 0.1087 | 0.0819 | 2.25 | 117,882.40 | -115.89 | -28.85 | -131.86 | -30.99 | 94.76 | -- | -1,066.62 | -441.76 | 3.30 | -6.85 | 0.5633 | -- | -5.29 | -18.45 | -239.17 | -- | -34.63 | -- |
| Alterity Therapeutics Ltd | 123.46k | -12.28m | 26.23m | 11.00 | -- | 0.7951 | -- | 212.42 | -0.005 | -0.005 | 0.00005 | 0.0063 | 0.0044 | -- | 1.52 | 11,223.64 | -44.20 | -53.02 | -53.57 | -61.96 | -- | -- | -9,947.97 | -40,995.62 | -- | -- | 0.0143 | -- | 557.60 | -39.40 | -7.47 | -- | -34.88 | -- |
| BPH Energy Ltd | 345.67k | 894.65k | 26.34m | 2.00k | 24.49 | 1.18 | -- | 76.20 | 0.001 | 0.001 | 0.0004 | 0.0203 | 0.0177 | -- | 5.97 | -- | 4.58 | -6.89 | 4.78 | -7.72 | 56.39 | -- | 258.50 | -357.76 | -- | -- | 0.0043 | -- | 96.54 | 5.21 | 179.13 | -- | -- | -- |
| Cann Group Ltd | 16.45m | -29.28m | 27.12m | 40.00 | -- | 0.5339 | -- | 1.65 | -0.0724 | -0.0724 | 0.0406 | 0.1161 | 0.1237 | 0.3952 | 7.37 | -- | -22.03 | -22.28 | -34.23 | -24.43 | 21.11 | -- | -178.07 | -407.57 | 0.0861 | -5.88 | 0.5646 | -- | 114.90 | 89.76 | -27.66 | -- | -11.16 | -- |
Data as of May 10 2024. Currency figures normalised to Chimeric Therapeutics Ltd's reporting currency: Australian Dollar AUD
